The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Long-term Outcomes of Valve-in-Valve Transcatheter Aortic Valve Implantation for Degenerate Homograft Aortic Valve Replacement

DOI: 10.4244/EIJ-D-20-00450

1. Heart Division, The Royal Brompton Hospital,, United Kingdom
2. Heart Division, The Royal Brompton Hospital, London, UK
3. Heart Divison, The Royal Brompton Hospital, London, UK
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

“Valve-in-valve” transcatheter aortic valve implantation (ViV-TAVI) is an alternative to conventional redo surgery for bioprosthetic aortic valve replacement (AVR) dysfunction (1) but ViV-TAVI for degenerate stentless bioprostheses is challenging (2). We report a single-centre consecutive-series 5-year follow-up of patients undergoing ViV-TAVI for degenerate homograft AVR. 

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic